Signaling Pathway

Histone Demethylase

Histone Demethylase

Related Products

PDF File 0.27MB

Histone Demethylase Inhibitors & Modulators (19)

Product Name Catalog No. Brief Description
CBB1003

HY-15774

CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

CBB1003 hydrochloride

HY-15774A

CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

CBB1007

HY-15313

CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).

CBB1007 hydrochloride

HY-15313B

CBB1007 Hcl is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).

CBB1007 trihydrochloride

HY-15313C

CBB1007 trihydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).

CPI-455

HY-100421

CPI-455 is a specific KDM5 inhibitor.

Daminozide

HY-13643

Daminozide(DMASA; DIMG; B 995), a plant growth regulator,  selectively inhibits the KDM2/7 JmjC subfamily.

DDP-38003 dihydrochloride

HY-19612A

DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC50 of 84 nM.

GSK-J1

HY-15648

GSK-J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX (IC50 = 60 nM for human JMJD3 in vitro).

GSK-J1 lithium salt

HY-15648D

GSK-J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX (IC50 = 60 nM for human JMJD3 in vitro).

GSK-J2

HY-15648A

GSK-J2 is a pyridine regio-isomer of GSK-J1 which poorly inhibits JMJD3 (IC50 > 100 μM), making it an appropriate negative control for in vitro studies involving GSK-J1; GSK-J1 is a selective inhibitor for human H3K27me3 demethylases.

GSK-J4

HY-15648B

GSK J4 is a cell permeable prodrug rapidly hydrolyzed by macrophage esterases to GSK-J1, a potent selective jumonji H3K27 demethylase inhibitor; attenuates lipopolysaccharide (LPS)-induced proinflammatory cytokine production in primary human macrophages (IC50 = 9 μM for the inhibition of TNFα release).

GSK2879552

HY-18632

GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.

IOX1

HY-12304

IOX1 is the most potent broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases; IC50 for KDM4A/KDM3A is 0.6/0.1 uM.

JIB-04

HY-13953

JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.

KDM5A-IN-1

HY-100014

KDM5A-IN-1 is an inhibitor histone demethylases.

ML324

HY-12725

ML324 is a potent JMJD2 demethylase inhibitor with demonstrated antiviral activity.

ORY-1001

HY-12782

ORY-1001 (RG-6016) is a potent LSD1 inhibitor extracted from patent WO2013057322A1.

SP2509

HY-12635

SP2509 is a novel histone demethylase LSD1 (KDM1A) antagonist with IC50 of 13 nM; no inhibition on MAO-A and MAO-B.